166 related articles for article (PubMed ID: 37255021)
21. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM; Kim YH; Horwitz SM; Dummer R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Trotman J; Taylor K; Dalle S; Weichenthal M; Walewski J; Fisher D; Dréno B; Stadler R; Feldman T; Kuzel TM; Wang Y; Palanca-Wessels MC; Zagadailov E; Trepicchio WL; Zhang W; Lin HM; Liu Y; Huebner D; Little M; Whittaker S; Duvic M;
Lancet; 2017 Aug; 390(10094):555-566. PubMed ID: 28600132
[TBL] [Abstract][Full Text] [Related]
22. [Management of mycosis fungoide : focus on brentuximab vedotin].
Lebas E; Collins P; Bonnet C; Libon F; Dezfoulian B; Nikkels AF
Rev Med Liege; 2021 Apr; 76(4):224-231. PubMed ID: 33830684
[TBL] [Abstract][Full Text] [Related]
23. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
[TBL] [Abstract][Full Text] [Related]
24. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
26. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
Oregel KZ; Everett E; Zhang X; Nagaraj G
Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
[TBL] [Abstract][Full Text] [Related]
27. Combination of brentuximab-vedotin with skin-directed therapies extends the time to the next therapeutic line in patients with cutaneous T-cell lymphoma.
Stranzenbach R; Stadler R
J Dtsch Dermatol Ges; 2021 Mar; 19(3):383-387. PubMed ID: 33617153
[TBL] [Abstract][Full Text] [Related]
28. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM
Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350
[TBL] [Abstract][Full Text] [Related]
29. Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy.
Baba Y; Sakai H; Kabasawa N; Harada H
Intern Med; 2023 Feb; 62(4):613-616. PubMed ID: 35871596
[TBL] [Abstract][Full Text] [Related]
30. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.
Oberic L; Delzor F; Protin C; Perriat S; Laurent C; Grand A; Canonge JM; Borel C; Gauthier M; Ysebaert L; Puisset F
J Oncol Pharm Pract; 2021 Oct; 27(7):1730-1735. PubMed ID: 33100177
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Svoboda J; Bair SM; Landsburg DJ; Dwivedy Nasta S; Nagle SJ; Barta SK; Khan N; Filicko-O'Hara J; Gaballa S; Strelec L; Chong E; Mitnick S; Waite TS; King C; Ballard H; Youngman M; Gerson J; Plastaras JP; Maity A; Bogusz AM; Hung SS; Nakamura H; Nejati R; Steidl C; Lim M; Ruella M; Schuster SJ
Haematologica; 2021 Jun; 106(6):1705-1713. PubMed ID: 32414850
[TBL] [Abstract][Full Text] [Related]
33. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
[TBL] [Abstract][Full Text] [Related]
34. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ; Horwitz SM; Advani R; Christensen JH; Domingo-Domenech E; Rossi G; Morschhauser F; Alpdogan O; Suh C; Tobinai K; Shustov A; Trneny M; Yuen S; Zinzani PL; Trümper L; Ilidge T; O'Connor OA; Pro B; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Iyer S
Blood Adv; 2022 Oct; 6(19):5550-5555. PubMed ID: 35470385
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review.
Henderson Berg MH; Davison K; Popradi G
Br J Dermatol; 2022 Feb; 186(2):379-381. PubMed ID: 34608632
[No Abstract] [Full Text] [Related]
36. Long term survival, time to next treatment and CD30 expression in patients with advanced CD30
Gosmann J; Stadler R
J Dtsch Dermatol Ges; 2022 Apr; 20(4):514-517. PubMed ID: 35319153
[No Abstract] [Full Text] [Related]
37. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
38. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
[TBL] [Abstract][Full Text] [Related]
40. Brentuximab vedotin in CD30
Stranzenbach R; Dippel E; Schlaak M; Stadler R
Br J Dermatol; 2017 Dec; 177(6):1503-1509. PubMed ID: 28703284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
